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Background
The goal of manufacturing process development for
drug substance and drug product is to establish a com-
mercial process capable of consistently producing drug
substance/drug product of the intended quality. Based
on regulatory requirements, the manufacturing process
has to be characterized prior to process validation. Since
performing the characterization study at the manufac-
turing scale is not practically feasible, development of a
scale down model that represents the performance of
the commercial process is essential to achieve reliable
process characterization. The developed scale down
model could also be applied for cell line selection, pro-
cess and medium development, raw material evaluation,
limit of cell age studies, process parameter excursions,
etc... Process development and commercial production
should not be on the critical path to market despite the
compressed time-to-market expectations. That is why
Technology Transfer (TT) is a vulnerable time for com-
panies. According to World Health Organization, Trans-
fer of technology is defined as “a logical procedure that
controls the transfer of any process together with its
documentation and professional expertise between
development and manufacture or between manufacture
sites”. In the pharmaceutical industry, Technology
Transfer refers to the processes that are needed for suc-
cessful progress from drug discovery to product devel-
opment to clinical trials to full-scale commercialization
or it is the process by which a developer of technology
makes its technology available to commercial partner
that will exploit the technology. This article describes
the strategies and activities required to develop a scale
down model. It also sketches a Technology Transfer
approach for bioprocesses by focusing on the upstream
part of a cell culture based process.
Results
Scale down model development strategy
“Small-scale models can be developed and used to sup-
port process development studies. The development of a
model should account for scale effects and be represen-
tative of the proposed commercial process. A scientifi-
cally justified model can enable a prediction of quality,
and can be used to support the extrapolation of operat-
ing conditions across multiple scales and equipment [2].
The key elements for designing a scale down model are
inputs (raw materials and components, cell source,
environmental conditions) and outputs (performance
and product quality metrics, sample handling/storage,
analytical methods). A scale down model can be equiva-
lent for some outputs but not for all and still be a repre-
sentative model. It should reproduce at small scale the
effect/impact seen at large scale. The acceptability of an
observed offset has to be statistically evaluated and
scientifically understood.
Technology Transfer strategy
“The goal of Technology Transfer activities is to transfer
product and process knowledge from development to
market, and within or between manufacturing sites to
support product commercialization. This knowledge
forms the basis for the manufacturing process,control
strategy, process validation approach and ongoing con-
tinual improvement [1]. A dedicated Technology Trans-
fer team has to be set up to facilitate and execute the
process including experts in different fields (production,
QA, QC, RA, MSAT, etc...). The whole Technology
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Transfer has to be coordinated by the technology trans-
fer/project leader. Organization for Technology Transfer
should be established and composed of both party
members from both sites, roles and scope of responsibil-
ities of each party should be clarified, and adequate
communication and feedback of information should be
ensured. Figure 1 describes the main steps of the Tech-
nology Transfer. Technology Transfer can be considered
successful if the Receiving Unit can routinely reproduce
the transferred product, process, or method against a
predefined set of specifications as agreed with the Send-
ing Unit. The success of a Technology Transfer project
will be largely dependent on the skill and performance
of individuals assigned to the project from the Sending
Unit and the Receiving Unit. The roles and responsibil-
ities of the sending unit and the receiving unit have to
be clearly defined. The documentation is a key element
of Technology Transfer: it ensures consistent and con-
trolled procedures for Technology Transfer and to run
the process. Clear documentation should provide assur-
ance of process and product knowledge (Table 1).
Conclusions
A scale down models is a tool for developing and char-
acterizing the process and should be designed and
demonstrated as appropriate representations of the
manufacturing process. The transfer of technology from
R&D to the commercial production site is a critical pro-
cess in the development and launch of a biotherapeuti-
cal product. The three primary considerations to be
addressed during an effective technology transfer are the
project plan, the people involved and the process.
Figure 1 Technology Transfer (TT) process flow chart.
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Table 1 Technology transfer documentation
Document Content
Bill of materials List of all components and their step of use (Supplier, grade)
Research and Development reports Historical data of pharmaceutical development of new drug substances and drug products at stage from
early development to final application of approval - Quality profiles of manufacturing batches (including
stability data) - Specifications and test methods of drug substances, intermediates, drug products, raw
materials and components, and their rationale - Change histories of important processes and control
parameters
Risk assessment Process flow charts - Scale up - Equipment changes - Media and feed preparation
Process descriptions Product information - Process step flow diagram - Cell culture steps description (cell line/ inoculum/
expansion/production bioreactor - Media and feed preparation - Harvest description - Raw materials/
equipment)
Technology transfer file Introduction - Manufacturing process description, process parameters - Equipment - Raw materials -
Analyses - Safety, environment - Stability (conditions, results) - Packaging (cold chain requirements, etc...) -
Cleaning - Shipment characteristics and proper validation if needed - Historical data available
Technology transfer protocol Technology transfer description - Scope - Objective - Responsibilities - Process Description - Equipment list
(receiving unit) - Raw material list - Reference of Master batch record/number of repetitions and status of
batches/acceptance criteria/relevant specifications/description of coaching
Manufacturing and testing description
of the process
Product information - Process step flow diagram - Cell culture steps description (cell line/inoculum/cell
expansion/production bioreactor) - Media and feed preparation - Harvest description (holding time/storage
conditions) - Raw materials - Equipments
Routine and non-sampling plans List of all the samplings that should be taken and kept in addition to the in-process control samples listed
in the manufacturing description
Data recording list Online and offline data to be monitored and recorded during the process
Deviation inventory Description in details of the deviations and reporting of the impact on the product titer and quality
Technology transfer report Technology transfer description - Objective - Scope - List of deviations and discussion - Process results and
comparison to acceptance criteria -, Conclusions
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